So we need protocolized extra steroids in new RA? A debate as old as time Individual patient data metaanalysis - slight gains early on, not sustained - fewer DMARD changes - but a heap more PNL, well after the protocol ends Life is about trade-offs😐 OP0220 #EULAR2023 @RheumNow https://t.co/M8SBKjGncv

#EULAR2023 #POS1066 “Diagnosis: Seropositive Nodular Rheumatoid Arthritis” - I can probably get rid of Nodular soon in my letter. Trends of Nodules have decreased over time. Could be because we are getting better at preventing erosion and smoking cessation @RheumNow https://t.co/fmQvyNHCUJ

Impact of menopause & on function in RA HAQ increases slightly after menopause Premature menopause = worse function Slightly better HAQ (but moderate & no effects on other PROs) in THR group vs. non THR No safety data @RheumNow OP0268 #EULAR23 https://t.co/7KJScF8O2X

Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w

#Scleroderma activity index #SCTC has an initial validated tool that is associated with death and organ damage with moderate correlations, so it has some degree of face validity ⁦@RheumNow⁩ #EULAR2023 ⁦@eular_org⁩ #OP0235 https://t.co/RDekhr7d2e

Initial use of glucocorticoids GC as bridging treatment in RA resulted in increase use of GC later, fewer DMARD changes later, van Ouwerkek L, Abst#OP220 #EULAR2023 @RheumNow https://t.co/IjxgQTZ8SE

>= 2 tophi and carotid plaque by ultrasound could independently predict major adverse cardiovascular events in addition to conventional CVD risk factors in #gout, data from a single center cohort of 262 pts with 10 yr follow up #EULAR2023 @rheumnow abst#OP0154

Malignancy in real world datasets: do we see differences between DMARDs - particularly JAKi, with ORAL Surveillance in mind? RABBIT German data (limited risk window): Point estimates slightly up vs TNFi, esp in high CV risk pts but magnitude not big OP0218 #EULAR2023 @RheumNow https://t.co/Ou7TgWvf3b

Scleroderma has an activity index that is associated w future morbidity & mortality. I wonder re the weightings of diff clinical manifestations as scleroderma renal crisis could weigh similarly to ex elevated CRP & a less severe manifestation. OP0235 @RheumNow #EULAR2023 https://t.co/KkimHBDVpg

#ClinicalPearl Updated #scleroderma Rx recommendations OP0234 New recommendations included ILD, early dcSSc 20 vs prior 16 guidelines. And they recommend ??! Won’t release yet due to importance of wording which will be finalized soon EULAR2023 @RheumNow @eular_org https://t.co/lES6pqkgeT

The JAK-pot study did not show any significant differences in MACE and other CV outcomes in RA patients treated with JAKi, slight increase signal in VTE/PE, Romain Aymon, Abst#OP0219 #EULAR2023 @RheumNow https://t.co/oPMnw2QmW3

#EULAR2023 POS1190-HPR Besides genetic influence, what do patients with #SLE think re: cause of the disease? A survey in N=290 in Sweden showed stress, hormones & infection as the next top 3 causes. Those reported the first two had different education & perceived health @RheumNow https://t.co/GhyCyp7EWU

We need to assess CV risk in IA but how? Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO Bummer: these 3 prediction tools are less accurate in IA but also OA. We need a dedicated tool. @Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe

Very much looking forward to our joint PRP-HRP-Rheum session later today How to improve & implement apps for self management in clinical care @ElenaNikiUK @fibrofella @ProfYelizPrior We will discuss and reveal the results of a survey made for #EULAR23 @RheumNow @eular_org https://t.co/R5vTW3FeWO

Interesting study presented by Dr Kent Kwoh in #KneeOA using the OAI data - effusion-synovitis produced heterogenous effects on pain reporting depending on the activity - walking, stairs, standing etc. effect not in bone marrow lesions @rheumnow abst#POS0108 #EULAR2023 https://t.co/MvI5z1KHlE